Data sets produced at the Texas A&M Tissue Chip Testing Center and at the University of Pittsburgh Drug Discovery Institute.
| View/Edit | Study Name | Start Date | Study Types | Experimental Models | Model Types | Disease(s) | Data Points | Data Points (omic) | Images | Videos | Plate Maps | Plate Reader Files | Supporting Data Files | Description | Reproducibility Status | Center | Data Entry | Review | Sign Off Date | Data Provider | ID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| View/Edit | TCTC Reference Study | 2018-01-30 | CC | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 329 | 0 | 0 | 0 | 0 | 0 | 0 | This study is a reference study done at the UPDDI for comparison with the SQL-SAL 1.5 models run for the TCTC project. Method: Determine chip to chip reproducibility in vehicle treated (1% DMSO) and 40 µM tolcapone treated SQL-Sal 1.5 devices during 14 day incubation. Results: chip to chip variation was at excellent to acceptable levels for albumin, urea and LDH. Comment: previous studies in this model showed significant reduction in liver functions at 88 and 220 uM tolcapone. The lack of the effect at 40 uM should be retested. | UPDDI | Dillon Gavlock | 4 | 2018-08-30 | Taylor_MPS | 40 | |
| View/Edit | TCTC Training | 2018-02-27 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 126 | 0 | 0 | 0 | 0 | 0 | 0 | Purpose: The goal of this experiment was to educate Courtney Sakolish from Texas A&M University on the construction and use of the SQL-SAL 1.5 liver model in a commercial Nortis devices. Methods: The SQL-SAL 1.5 liver model was constructed in 6 Nortis devices for 14 day treatment to vehicle control or 88 and 220 μM tolcapone. Results: Albumin, urea synthesis was decreased, LDH release was increased in devices treated to tolcapone as compared to vehicle only treated devices. | UPDDI | Dillon Gavlock | 4 | 2018-09-18 | Taylor_MPS | 152 |